Global Ovarian Cancer Drugs Market 2019-2023
SKU ID : TNV-14770463 | Publishing Date : 01-Feb-2019 | No. of pages : 117
Detailed TOC of Global Ovarian Cancer Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Epithelial ovarian cancer - Market size and forecast 2018-2023
• Germ cell ovarian cancer - Market size and forecast 2018-2023
• Stromal cell ovarian cancer - Market size and forecast 2018-2023
• Small cell ovarian cancer - Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Clovis Oncology
• F. Hoffmann-La Roche
• Spectrum Pharmaceuticals
• TESARO
PART 14: APPENDIX
• Research methodology
List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Epithelial ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Epithelial ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 23: Germ cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Germ cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 25: Stromal cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Stromal cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 27: Small cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Small cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Decision framework
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AstraZeneca - Vendor overview
Exhibit 51: AstraZeneca - Product segments
Exhibit 52: AstraZeneca - Organizational developments
Exhibit 53: AstraZeneca - Geographic focus
Exhibit 54: AstraZeneca - Key offerings
Exhibit 55: Clovis Oncology - Vendor overview
Exhibit 56: Clovis Oncology - Product segments
Exhibit 57: Clovis Oncology - Organizational developments
Exhibit 58: Clovis Oncology - Geographic focus
Exhibit 59: Clovis Oncology - Key offerings
Exhibit 60: F. Hoffmann-La Roche - Vendor overview
Exhibit 61: F. Hoffmann-La Roche - Business segments
Exhibit 62: F. Hoffmann-La Roche - Organizational developments
Exhibit 63: F. Hoffmann-La Roche - Geographic focus
Exhibit 64: F. Hoffmann-La Roche - Segment focus
Exhibit 65: F. Hoffmann-La Roche - Key offerings
Exhibit 66: Spectrum Pharmaceuticals - Vendor overview
Exhibit 67: Spectrum Pharmaceuticals - Business segments
Exhibit 68: Spectrum Pharmaceuticals - Organizational developments
Exhibit 69: Spectrum Pharmaceuticals - Geographic focus
Exhibit 70: Spectrum Pharmaceuticals - Key offerings
Exhibit 71: TESARO - Vendor overview
Exhibit 72: TESARO - Business segments
Exhibit 73: TESARO - Organizational developments
Exhibit 74: TESARO - Geographic focus
Exhibit 75: TESARO - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations
Keyplayers in Global Ovarian Cancer Drugs Market 2019-2023
AstraZenecaClovis Oncology
F. Hoffmann-La Roche
Spectrum Pharmaceuticals
TESARO